How do I hire a fractional VP of Sales for a medtech company in 2027?

The job this role is actually hired to do

A fractional VP of Sales is not a discounted full-time executive. It is a specific instrument for a specific problem: you have revenue signal but no repeatable motion, and the person who could build that motion costs more in salary, equity, and search time than your stage can absorb. The fractional structure buys you the pattern recognition without the permanent overhead.

In medtech, the problem usually shows up in one of four shapes. First, the founder-led ceiling: the clinical founder or CEO closed the first eight to fifteen accounts personally, and now the calendar cannot hold both product work and pipeline work. Second, the process vacuum: you have three or four reps, everyone sells differently, forecasts are guesses, and nobody can explain why a deal stalled. Third, the launch problem: a second product line, a new call point (moving from the cath lab to the OR, or from the clinic to the IDN), or a new geography that the existing team has no reference frame for. Fourth, the bridge: your VP left, the search will take five to seven months, and the team will drift without leadership in the interim.

Match the shape to the engagement or you will misdiagnose the hire. A founder-led ceiling needs a builder who documents, not a closer who out-sells your reps. A process vacuum needs someone who lives in CRM hygiene, stage definitions, and coaching cadence. A launch needs a person who has taken a device or diagnostic from zero to first commercial revenue and knows what a reimbursement gap does to a forecast. A bridge needs stability and a clean handoff document, not a reinvention of everything the permanent hire will inherit.

Be honest about the floor. If you have fewer than three or four quota-carrying reps and revenue in the low seven figures or below, a fractional VP of Sales is usually the wrong shape. At that stage you need a player-coach — someone who carries a bag and also builds the early process — because a leader with no team to lead will spend the engagement writing documents nobody executes. The inverse also holds: past roughly $10M in annual revenue with a team of ten or more, the coordination cost of a part-time leader starts to exceed the savings, and you should be running a full-time search with the fractional person bridging it.

Adjacent roles are worth knowing so you buy the right one. A fractional CRO owns the whole revenue function — marketing, sales, customer success, partnerships, and the RevOps layer underneath — and is the right call when your problem spans functions rather than sitting inside sales. A fractional sales operations lead fixes systems, territory design, comp plans, and reporting without owning the number. A sales enablement contractor builds content and certification but does not manage people. A channel or distributor consultant matters enormously in medtech, where independent rep networks and distributor agreements can carry more revenue than the direct team. Companies frequently buy the VP title when what they actually needed was one of these narrower, cheaper engagements.

Why medtech changes the specification

The single biggest hiring mistake here is treating medtech like enterprise software with a longer cycle. It is a structurally different sale, and a leader who only knows subscription software will apply the wrong reflexes with confidence.

Start with the buying committee. In software you might face a champion, an economic buyer, and a security reviewer. In medtech you often face the clinician who will use the device, the department head who owns the budget line, a value analysis committee that meets monthly or quarterly, supply chain and procurement, biomedical engineering, legal, compliance, sometimes infection control, and — for anything touching data — IT and privacy. Each of these can stop the deal without any of them being able to start it. A leader who has not sat in a value analysis committee submission cycle will consistently under-forecast, because the committee calendar, not the champion's enthusiasm, sets the close date.

Then the evidence burden. Clinical buyers ask for peer-reviewed data, comparative outcomes, and often a local evaluation before purchase. Your reps must be able to discuss a study's design and limitations without wandering into claims the regulatory clearance does not support. That constraint is not a nuance — it is a hard boundary. A sales leader who coaches reps to "just tell them it also works for X" when X is outside the cleared indication has created a compliance problem, not a pipeline. Ask candidates directly how they trained teams to handle off-label questions, and listen for whether they route to medical affairs or improvise.

Reimbursement is the third structural difference. If the buying institution cannot get paid for using your product, clinical enthusiasm does not convert. Coverage, coding, and payment are three separate questions, and a candidate who conflates them has not sold in this world. Ask how they built a call plan when reimbursement was still pending, or how they handled a product that required a facility to absorb cost against a bundled payment. The answers reveal more than any deal-size number on a résumé.

Contracting mechanics matter too. Group purchasing organization agreements, integrated delivery network master agreements, capital equipment budget cycles, and trial-to-conversion terms all shape how revenue actually lands. A device sold on a placement-and-consumables model forecasts nothing like a capital purchase, and a leader who has only done one will build the wrong compensation plan for the other. Similarly, if your commercial model runs through independent distributors or 1099 rep groups, the leadership job is largely channel management — recruiting, terminating, and motivating people you do not employ — which is a genuinely different skill from managing W-2 reps.

Finally, quality and post-market obligations touch sales more than outsiders expect. Complaint handling, field action support, and documentation discipline all run partly through the commercial team. A candidate who treats these as someone else's problem will create friction with your quality organization within weeks.

How the role fits your RevOps stack

A fractional leader inherits whatever systems you already have, and in most medtech companies at this stage those systems are partial. The first thirty days are usually diagnostic: what does the CRM actually contain, what do the stages mean, who touches the data, and which numbers does the board see.

Expect the engagement to touch four layers. The data layer is your CRM and its object model — accounts that are facilities rather than companies, contacts who move between institutions, opportunities that need to model committee gates rather than generic stages. Many medtech CRMs are misconfigured at exactly this point: they were set up from a software template, so there is nowhere to record the value analysis submission date, the evaluation start, or the distributor of record. The process layer is stage definitions, exit criteria, qualification framework, and forecast categories. The enablement layer is the objection library, the clinical evidence packet, the demo or in-service protocol, and the onboarding path for a new rep. The measurement layer is the weekly pipeline review, the inspection cadence, and the small set of leading indicators the founder and board will actually watch.

A capable fractional leader will not rebuild all four at once. The usual sequence is process first (because it costs nothing but thinking), then measurement (so you can see whether the process is being followed), then enablement, then data-layer changes last — because CRM surgery mid-quarter is how you lose a quarter of history. If a candidate proposes replacing your CRM in week two, that is a signal to slow down, not speed up.

One structural warning. The fractional leader should build artifacts that survive their departure, not dependencies that require their presence. The test is simple: at any point in the engagement, could your senior rep run Monday's pipeline review from the written cadence document without the fractional leader on the call? If the answer is no at month four, you have bought a contractor, not a leader.

Downstream effects are worth planning for. A working forecast changes how you talk to your board and your lenders. Clean stage data changes what marketing can target. A documented onboarding path changes your hiring velocity, because you can bring on a rep without the founder personally training them. These second-order benefits often outlast the revenue lift from the engagement itself, and they are worth naming explicitly in the scope so they get built rather than assumed.

Pricing, engagement models, and what drives the range

Fractional pricing is not standardized, and anyone who quotes you a universal market rate is guessing. What is consistent is the set of variables that move the number, and you can negotiate intelligently once you know them.

Days per month is the primary driver. Common structures run from a light advisory engagement of four to six days per month — realistically a coach for your founder, not a leader for your team — through a working engagement of ten to fifteen days, up to a near-embedded twenty-day arrangement that approaches full-time. Below eight days per month, expect strategy and review; do not expect the person to actually manage reps, because management is a high-frequency activity and biweekly check-ins do not change behavior.

Scope breadth moves it next. Managing an existing team is cheaper than building one. Building one is cheaper than building one while also launching a product and negotiating a distributor network. Every additional workstream adds real hours and should add real cost.

Regulatory and clinical complexity carries a premium because the qualified candidate pool is small. There are many capable sales leaders. There are far fewer who have carried a device through hospital committee processes, and fewer still who have done it in your specific call point. Scarcity prices accordingly.

Travel is the most commonly underestimated line. Medtech is a relationship business conducted in person — hospital visits, case coverage, trade shows, distributor meetings. Decide up front whether travel days count against the monthly day commitment or sit outside it, and who pays expenses. This single ambiguity causes more mid-engagement friction than rate disagreements do.

Equity appears in maybe a third of arrangements and should be treated carefully. Meaningful equity makes sense only when the engagement is expected to run twelve months or longer and the person is genuinely operating as an executive. Standard practice is a normal option grant with a cliff and multi-year vest, sized well below what a full-time executive would receive, with the cash rate reduced correspondingly if you want the equity to be real rather than decorative. Do not use equity as a way to underpay for near-full-time work; the incentives break within a quarter.

Three structures dominate. A flat monthly retainer for a defined day commitment is the most common and the easiest to administer. Milestone-based pricing ties payment to deliverables — playbook complete, two reps hired and onboarded, forecast accuracy within a defined band for two consecutive months — and works well when you can define outcomes crisply. A hybrid puts a base retainer underneath a smaller performance component tied to something the leader genuinely controls, like pipeline generated or reps ramped, rather than closed revenue in a market with an eighteen-month cycle.

Avoid pure commission arrangements outright. In a market where a deal signed in March may have started the prior spring, a commission-only leader either starves or starts poaching your existing pipeline to survive. Both outcomes damage you. Equally, avoid open-ended hourly billing without a cap; it converts every conversation into a metered event and discourages exactly the informal coaching you are paying for.

Budget the surrounding costs too. Travel, a CRM seat, sales tooling, conference attendance, and the occasional contractor the leader will want to bring in for a specific gap all sit outside the retainer. A common planning error is approving the retainer and then declining every request that would make it effective.

How to source, screen, and shortlist

Generic job boards fail for this role in a predictable way: they generate volume without signal. You will receive hundreds of applications, most from full-time job seekers labeling themselves fractional while they search, and the medtech-plus-fractional intersection will be nearly absent. Spend your sourcing effort elsewhere.

Your board, investors, and clinical advisory network are the highest-yield channel. Medical device commercial leadership is a small community; three well-placed asks usually produce two credible names. Ask specifically — "who ran commercial for a company selling into the OR at our stage" beats "know any sales leaders."

Professional operator communities are the second channel. Revenue-leadership communities and RevOps-focused groups host large numbers of practicing operators, many of whom take fractional work between or alongside roles. Industry associations in medical technology and clinical specialty societies are worth mining for people who have presented or served on committees — that presence signals genuine domain immersion.

Former distributor principals and independent rep group owners are an underrated pool. They have run P&Ls, recruited and fired sellers, and negotiated with hospitals — and many are open to fractional arrangements. They may be weaker on CRM and forecasting rigor, which you can supplement.

Adjacent regulated industries are a legitimate fallback. Someone who has sold diagnostics, laboratory equipment, life-science instrumentation, or clinical software carries most of the relevant reflexes. Pharma is a partial match — the call point overlaps, the contracting does not. If you go this route, pair the person with a domain advisor for the first quarter and say so openly in the offer.

Screen in two rounds, not six. Strong candidates have options and long processes read as indecision.

Round one, roughly forty-five minutes, focused on domain. Ask them to walk through one deal end to end — who the committee members were, what each one needed, where it stalled, and what unstuck it. Ask what they did when reimbursement was unfavorable or unresolved. Ask how they handled an off-label question from a clinician. Ask what their reps were required to log in CRM and what happened when they did not. Vague answers here are disqualifying regardless of the logo history.

Round two, roughly ninety minutes, focused on process and fit. Ask for a rough first-ninety-days plan — not a polished deck, a verbal sketch of week one, week four, and week twelve. Ask how they measure their own contribution in a fractional seat, because the honest answer involves leading indicators, not revenue. Ask their communication cadence with a founder and what they escalate versus absorb. Ask how many concurrent engagements they hold and how long each has run.

Two exercises separate the strong from the merely fluent. The deal autopsy: hand them a recent loss, anonymized, and ask what they would have done differently. Fluent candidates narrate the loss back to you; strong candidates identify the qualification failure that made it predictable. The live coaching sample: have them run a fifteen-minute pipeline review with one of your actual reps while you observe. You will learn more in that quarter hour than in three interviews, because coaching is the job and it cannot be faked in the abstract.

Reference-check with specificity. Ask each reference what measurably changed in the first ninety days, what the person's biggest weakness was, and whether they would hire them again for the same problem or a different one. Ask for a reference who is not on the provided list — a rep who reported to them, ideally.

Watch for the leader carrying too many concurrent clients to be effective. Three or more simultaneous engagements at meaningful day counts is arithmetically difficult, and the client who suffers is whoever escalates least. Ask for the list.

A decision framework before you commit

Run the decision as a sequence rather than a single judgment. Most bad fractional hires are diagnosis failures, not selection failures — the company bought a leader when it needed a seller, or bought a bridge when it needed a rebuild.

Structure the contract to make the framework enforceable. Define scope as deliverables, not hours: a documented playbook, a hiring plan with scorecards, a functioning weekly review, a forecast within a stated accuracy band. Set a minimum day commitment with a stated travel policy. Include a thirty-day notice for either party. Assign IP explicitly — every process, template, scorecard, and playbook created during the engagement belongs to your company, and this clause is worth insisting on because it is the difference between buying an asset and renting attention. Add the confidentiality and, where relevant, quality-system and regulatory-training obligations your compliance function requires, plus a conflict clause preventing simultaneous work with a direct competitor.

Then measure the right things. In the first ninety days, judge on leading indicators: is the process written down, are stages defined and used, has forecast variance narrowed, are reps demonstrably better in call reviews, and can you personally explain the sales motion to an investor without the fractional leader in the room. Closed revenue in ninety days is largely a function of pipeline that existed before they arrived. By month six you should see pipeline coverage improve, stalled deals decline, and time-in-stage shorten at the specific gate the diagnostic identified. If none of those have moved by month six, rescope or end it — waiting until month twelve is a common and expensive form of hope.

Plan the exit at the start. Every engagement ends in one of three ways: conversion to full-time, handoff to a promoted internal leader, or wind-down. Name the intended path in the contract, define what the handoff document must contain, and build a two-to-four-week transition into the terms. An engagement without a defined ending tends to drift into an expensive advisory relationship that nobody wants to be the one to cancel.

Related questions

Should a medtech company hire a fractional CRO instead?

Choose a fractional CRO when the problem crosses functions — marketing generating unqualified leads, customer success failing to drive reorders, partnerships undefined. Choose a fractional VP of Sales when the gap is squarely in sales execution and team management. Below roughly $10M revenue, the narrower sales role is usually sufficient.

Can the engagement work fully remotely?

Partially. Diagnostic work, playbook building, forecasting, and coaching travel well over video. Hospital relationships, case coverage, distributor meetings, and trade shows do not. Most effective arrangements are hybrid, with several on-site or in-field days per month built explicitly into the day commitment and travel policy.

How long should the engagement run?

Six to twelve months is typical. Under six months you rarely see process change take hold, since one medtech sales cycle may not even complete. Past twelve months, either convert to full-time, hand off to an internal leader, or acknowledge you have created a permanent part-time dependency.

What if no candidate has direct medtech experience?

Widen to adjacent regulated sales — diagnostics, lab instrumentation, clinical software, life-science tools — and pair the hire with a domain advisor for the first quarter. Verify they have sold through committee-based buying with evidence requirements. Do not accept a pure subscription-software background without that adjacency.

Who inside the company should own the relationship?

The CEO or founder, directly, for the first ninety days. Fractional leaders fail most often from ambiguous authority — reps unsure whether to follow them, functions unsure whether to prioritize their requests. A weekly standing session with the CEO, plus an explicit announcement of scope and authority to the team, prevents most of it.

FAQ

How many days per month is enough to actually manage a team?

Roughly ten days is the practical floor for genuine management. Below that, the cadence is too sparse to inspect pipeline weekly, coach individual reps, and still handle escalations. Four to six days per month buys advisory input and strategic review, which is valuable but different — do not scope it as leadership and then be disappointed that behavior did not change.

Should equity be part of the deal?

Only when the engagement is expected to run twelve months or more and the person is functioning as a genuine executive with authority over the number. Use a standard option grant with a cliff and multi-year vest, sized well below a full-time executive package, and reduce cash correspondingly if you want the equity to carry real weight rather than serve as decoration.

What is the single biggest red flag in an interview?

A candidate who proposes compressing a long clinical sales cycle through generic tactics — heavier discounting, aggressive outbound volume, free trials — without discussing the committee calendar, evidence requirements, or reimbursement path. That answer reveals a software reflex applied to a regulated purchase, and it will produce a quarter of wasted activity before the mismatch becomes obvious.

How do I stop the engagement from creating dependency?

Write the exit into the contract at signing. Require that every process be documented and owned by the company, name the handoff target, and test periodically whether your senior rep could run the weekly review from the written cadence alone. If the answer stays no past month four, escalate it as a scope problem rather than waiting for the engagement to end.

Can this work alongside an existing distributor or independent rep network?

Yes, and it is often exactly the right fit, but the specification changes. Channel leadership is about recruiting, motivating, and occasionally terminating people you do not employ, with limited direct authority over their time. Screen specifically for that experience — a leader who has only managed W-2 reps will apply direct-management reflexes that a distributor principal will simply ignore.

What does a fair 90-day pilot look like?

A paid engagement at the intended day rate with three or four written deliverables due by day ninety — a documented sales process with defined stages, a functioning weekly pipeline review, a hiring scorecard, and a diagnostic memo on the biggest constraint. Review against those specifically, then extend, rescope, or end. Do not run an unpaid trial; strong candidates decline them.

Sources

• U.S. Food and Drug Administration — Medical Devices
• FDA — 510(k) Premarket Notification
• Centers for Medicare & Medicaid Services — Coverage
• AdvaMed — Advanced Medical Technology Association
• U.S. Department of Health & Human Services — HIPAA
• Harvard Business Review — Sales
• Pavilion — Revenue Leadership Community
• MedTech Dive — Industry News
• SHRM — Talent Acquisition Resources

Related on PULSE

• How to structure a 90-day plan for a new sales leader
• Fractional CRO vs fractional VP of Sales: which one fits your stage
• Building a pipeline review cadence that survives leadership change
• Sales compensation design for long-cycle regulated markets
• What RevOps should fix before hiring a sales leader